Erratum: 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS): Developed by the task force on cardio-oncology of the European Society of Cardiology (ESC).

Registry-linked trialOpen access · bronzeAbstract readPublished Erratum

In one paragraph

Article in European heart journal. Cardiovascular Imaging, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06039735 (Cardiac Toxicity and Prognostic Value of New Echocardiographic Indicators in the Treatment of Primary Multiple Myeloma), which is not on this map. Cited by 6 papers.

0numbers the graph read from it

0cells of the map it votes in

6citing papers in PubMed

4.2field-weighted citation impact, top 5% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06039735 recruitingnot on this map

Cardiac Toxicity and Prognostic Value of New Echocardiographic Indicators in the Treatment of Primary Multiple Myeloma

TypeobservationalSponsorQilu Hospital of Shandong UniversityRan2023 to 2028Enrolled50ConditionsMultiple MyelomaArmsChemotherapy and/or autologous hematopoietic stem cell transplantation

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 19 citations in OpenAlex.

Metabolic reprogramming in radiation-induced heart disease: the emerging role of PET imaging.Frontiers in cardiovascular medicine · 2026
Review
The multifaceted mechanisms of Tanshinone IIA in doxorubicin-induced cardiotoxicity.Frontiers in medicine · 2026
Review
Risk of cardiovascular-related death after radiotherapy for thoracic cancer.Radiation oncology (London, England) · 2025
Article
Long-term risks and benefits of oral anticoagulation in atrial fibrillation patients with cancer: A report from the GLORIA-AF registry.European journal of clinical investigation · 2025
Article
Association between Active Cancer and Risk of Thrombotic and Cardiovascular Outcomes in Outpatients with COVID-19: A CORONA-VTE Network Analysis.TH open : companion journal to thrombosis and haemostasis · 2025
Article
Isolated Pericardial Effusion Without Associated Myocarditis in a Small-Cell Lung Cancer Patient Undergoing Atezolizumab Therapy.Cureus · 2024
Article

4 · The record

Corrections and comments

Erratum for
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS).2022

5 · Who and what money

Authors and funding

0 authors.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID37076917

DOI10.1093/ehjci/jead080

OpenAlexW4366463166

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

NCT06039735ClinicalTrials.gov

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.